



Annual General Meeting
28 November 2024

Syntara Board

Significant international pharmaceutical experience



Dr Kathleen Metters
Chair

- Former Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of the company's global research projects.
- In a subsequent role at Merck & Co she led work on External Discovery and Preclinical Sciences 1a).
- Former CEO of biopharmaceutical company Lycera Corp.



Dr Simon Green
Non-Executive Director

- Experienced senior global pharma executive with 30 years' of experience in the biotechnology industry.
- Actively involved in CSL's global expansion over a 17-year period where he held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia.
- Prior to joining CSL he worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation.



Gary Phillips
Chief Executive Officer

- 30+ years' of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
- Joined Syntara in 2003 and was appointed Chief Executive Officer in March 2013 at which time he was Chief Operating Officer.
- Previously held country and regional management roles at Novartis – Hungary, Asia Pacific and Australia.



Hashan De Silva
Non-Executive Director

- Experienced life sciences investment professional with extensive knowledge of the biotech, pharmaceutical and medical technology sectors.
- Worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research.
- Prior to moving into life science investment Hashan worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.

Syntara 2024 AGM



Agenda

1. Welcome and opening of meeting
2. Address by Board Chair
3. Presentation by CEO
4. Shareholder questions
5. Formal business:
 - i. Financial Report, Directors' Report and the Auditor's Report
 - ii. Resolution 1 - Adoption of the Remuneration Report
 - iii. Resolution 2 - Re-election of Dr Kathleen Metters as a Non-Executive Director
 - iv. Resolution 3 - Grant of Performance Rights to Mr Gary Phillips
 - v. Resolution 4 - Approval of the Company's Employee Option Plan/ Performance Rights Plan
 - vi. Resolution 5 - Appointment of Auditor
6. Meeting close

Online question process



To submit a written question:

- Select the 'Q&A' option on the centre bottom toolbar
- Type out your question in the text box provided and submit

To ask a question verbally:

Click the 'raise hand' button on the centre bottom toolbar at the appropriate time. When the presenter prompts you to ask your question, you will be provided with microphone access, the system will ask you to confirm your microphone settings, and once confirmed you will be able to speak.

Online voting process

To vote online visit: <https://web.lumiagm.com/#/359067989>

When the poll is open, select the vote icon

To vote, select either For, Against or Abstain

You will see a vote confirmation

To change or cancel your vote “click here to change your vote” at any time until the poll is closed

For full details on how to log on and vote online, please refer to the user guide available at <https://www.reportsonline.net.au/?documentid=5E9AACDA6DAC449C95B1382697872B72>



Address by Board Chair

Dr. Kathleen Metters, Chair
28th November 2024

Syntara acknowledges the traditional custodians of the lands on which we meet and pay our respects to their Elders past and present.



AGM – CEO Report

Gary Phillips, CEO
28th November 2024



Forward looking statement

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and

involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.



Investment Highlights



Australian-founded **clinical stage drug developer**.



Backed **by specialist healthcare investors** – 52% institutional.



Focus on first-in-class and best-in-class drugs backed by **in house long-life patent portfolio**.



Funded to mid-2025 with **near term data to drive value** over 12-18 months.



Multiple shots on goal from additional Phase 2, Phase 1 and preclinical assets.



Experienced team with **proven track record** in licensing deals – \$100m raised.



Three Phase 2 studies in **blood cancer indications** with addressable market value >\$4.5 bn.



\$8.5m in non-dilutive grant funding awarded in last 3 years.

Shareholders & cash

Financial Information (ASX: SNT)

Share price – 27 November 2024	\$0.048
Market cap	A\$65.9m
Proforma cash balance (30 Sep 2024) ¹	A\$10.4m
Enterprise value	A\$55.5m

Note:

1. Proforma cash of \$10.4m includes: cash (\$4.34m); 2024 R&D tax credit (\$4.56m); return of security deposit (\$0.9m) proceeds from the sale of the MBU (\$0.6m).

Institutional Ownership

30 Sept 24

D&A Income Limited	19%
Platinum Investment Management Limited	15%
BVF Partners LP	7%
Total Institutional Ownership	52%

Share Price & Volume - YTD




*22 January volume 78.66m — crossing of stock between institutions after closure of fund

Syntara is the global leader in lysyl oxidase chemistry and biology

Multi year research program leveraged with extensive scientific collaborations worldwide has delivered three drugs now in phase 1c/2 studies

Lysyl oxidases mediate the final stage in fibrosis



Lysyl oxidase inhibition provides a true anti-fibrotic therapy, directly addressing the tissue stiffening that occurs due to increases in collagen and number of cross-links.

SNT-5505 in Oncology

- Clinical PoC: reduction of bone marrow collagen fibrosis grade in 45% of evaluable myelofibrosis patients in 6-month Phase 2 study
- Excellent clinical safety and tolerability with a complementary mode of action to current standard of care
- INDs approved for myelofibrosis and hepatocellular carcinoma
- Potential in haematological indications such as MDS as well as solid tumours; two Nature publications
- Patent priority date of 2018 provides extended IP coverage

Topical pan-LOX inhibitors in Skin Scarring

- Clinical PoC: significant reduction of collagen and good safety in 3-month placebo-controlled Phase 1c study in patients with established scars
- Lead and back up compounds to support studies in multiple scar types (prevention of scar formation and modification of existing scars) in topical and oral dosage form
- Strong preclinical evidence in models of skin fibrosis and scarring; Nature publication
- Patent priority date of 2019 provides extended IP coverage


Myelofibrosis

A rare type of bone marrow cancer that disrupts the body's normal production of blood cells

Key Facts

- Affects ~15 in 1m people worldwide
- Age of onset typically from age 50; 5 years median survival
- 11% transformation to leukemia
- Reduced red blood cells can cause extreme tiredness (fatigue) or shortness of breath
- Reduced white blood cells can lead to an increased number of infections
- Reduced platelets can promote bleeding and/or bruising
- Spleen increases blood cell production and becomes enlarged
- Other common symptoms include fever, night sweats, and bone pain.

Primary Myelofibrosis is characterised by a build up of scar tissue (fibrosis) in bone marrow reducing the production of blood cells.



Current standard of care (SoC): JAK inhibition

- Symptomatic relief plus some limited survival improvement.
- 75% discontinuation at 5 years
- Median overall survival is 14 – 16 months after discontinuation

Commercial Opportunity

- Current SoC; revenue ~US\$1b per annum
- Recent history of biotech exits in excess of US\$1.7b

SNT-5505

In contrast to SoC SNT-5505 intervenes at the source, clearing fibrosis from the bone marrow and enabling the production of healthy blood cells to resume

Clinical positioning

- Distinct mode of action, improved tolerability and a profile suitable for combination with SoC
- In addition to symptomatic relief, potential for disease modification.

PXS-5505 Phase 2 Trial (MF-101) monotherapy; Expert review

- “PXS-5505 continues to show not only an excellent safety profile but also promising clinical activity. The effect on bone marrow fibrosis is particularly exciting for a disease like myelofibrosis, where despite numerous years of research, we do not have any effective anti-fibrotic drugs.”
- “It is encouraging to see that majority of 10 patients who completed 24 weeks of therapy also had improvements of symptoms and more importantly, stable or improved blood counts; including in those patients with severe thrombocytopenia.”
- “These results support plans to continue clinical investigation of the agent, including combinations with JAK inhibitors where the lack of overlapping hematological toxicity would make PXS-5505 an ideal add-on candidate.”



Dr. Lucia Masarova

Assistant Professor, Department
of Leukemia at MD Anderson
Cancer Center, Houston

Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor

Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure

Design	Treatment Cohort	Endpoints
FDA reviewed interim monotherapy data and combination therapy protocol Q3 2023 Open label Phase 2a 52 week treatment period 15 patients SNT-5505 200mg BID + stable dose of RUX	Int-2/high risk PMF or post-ET/PV MF Treated with RUX ≥ 12 weeks (stable dose for ≥ 8 weeks) and not achieved complete remission per IWG criteria Population enriched with patients who reach predetermined thresholds in bone marrow fibrosis and symptom score	PRIMARY Safety SECONDARY PK/PD BMF Grade IWG Response SVR Hematology Symptom score Platelet response RUX dose modifications

ClinicalTrials.gov ID NCT04676529

Safety Monitoring Committee (SMC) – 30 May 2024

- SMC consists of all Study Investigators, CRO Medical Monitor and Sponsor representative.
- 10 patients reviewed, 5/10 at 3 months
- Unanimous agreement from all voting members to continue the study

* JAKi – Janus Kinase inhibitor, RUX – Ruxolitinib, MF myelofibrosis, ET Essential Thrombocythaemia, PV polycythaemia vera, INT intermediate, BMF bone marrow fibrosis, PK pharmacokinetics, PD pharmacodynamics, SVR spleen volume response, IWG International Working Group Myeloproliferative Neoplasms

Study Plan

- 19 clinical trial sites
- Recruitment started 13 Dec 2023
- **Fully recruited (August 2024)**

Interim 6 months data targeted for Dec 2024 at American Society of Hematology

- Top line data expected mid 2025

Further interim data in Q1 2025 to drive FDA discussion on pivotal study design and potential partnering interest

Strong interest in myelofibrosis assets from strategics



Date of Announcement	Feb-2024	June-2023	July-2022
Drug Name	Pelabresib	Pacritinib	Momelotinib
Lead Indication / Phase (at transaction)	Myelofibrosis (Successful Phase 3 studies)	Myelofibrosis (Marketed)	Myelofibrosis (FDA Filed – June)
Deal Type	Acquisition	Acquisition	Acquisition
Upfront / Milestones (USD)	US\$2.9B	US\$1.7B	US\$1.9B
Earnout Payments / Royalty Rate (%)	Subject to regulatory approvals	None	None

Potential to deliver near term value

Pipeline creates multiple opportunities in high value markets

Drug Candidate	Indication	Phase	Anticipated Upcoming Milestones	Addressable market (US\$)
SNT-5505	Myelofibrosis	Phase 2	Interim 6 month data December 2024	~\$1 billion¹
	Myelodysplastic Syndrome Low & intermediate Risk + High risk trials	Phase 1c/2	Low/Int Risk Data H2 25 High Risk Data H2 25	~\$3.2 billion²
Oral and Topical Pan-LOX inhibitors	Scar prevention	Phase 2	Data H2 2025	~\$3.5 billion³
	Modification of scarring process	Phase 1c	Pilot study in keloid scars planned	~\$3.5 billion⁴
SNT-4728	IRBD and Parkinson's Disease	Phase 2	Data H2 2025	~\$3.5 billion⁵

1) MF: Addressable market, The Myelofibrosis market size across the 8MM was valued at \$2.39 billion in 2021 : <https://www.globaldata.com/store/report/myelofibrosis-market-analysis/>

2) MDS: Addressable market, MYELODYSPLASTIC SYNDROME TREATMENT MARKET ANALYSIS, <https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775>

3) Scar Prevention: Global Scar Market 2020 page 40 and 71; Total scar treatment market in 2019 exceeded US\$19b. Keloid and hypertrophic scar segment ~US\$3.5b

4) Scar modification: Addressable market, Global Scar Market 2020 page 40 and 71. Total scar treatment market in 2019 exceeded US\$19b. Keloid and hypertrophic scar segment ~US\$3.5b

5) IRBD / Parkinson's Addressable market, Parkinson's Disease market size across the 7MM was valued at \$3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. <https://www.globaldata.com/store/report/parkinsons-disease-major-market-analysis/>



Shareholder Questions

Annual General Meeting, 28 November 2024



Formal Business

Annual General Meeting, 28 November 2024

First Item of Business

Financial Report, Directors' Report and Auditor's Report



No shareholder vote is required.

To receive and consider the financial report, directors' report and the auditor's report of the Company for the financial year ended 30 June 2024.

Resolution 1

Adoption of the Remuneration Report



Ordinary resolution (advisory vote only):

“That the remuneration report of the Company for the year ended 30 June 2024 be adopted.”

Resolution 1

Adoption of the Remuneration Report



The Company has received:

638,891,300 proxy votes in favour of the resolution;

3,172,205 proxy votes against the resolution;

5,336,800 proxy votes abstaining from the resolution;

6,856,203 proxy votes excluded from voting;

26,529,951 proxies able to be voted by the chair/board which the chair/board intend to vote in favour of the resolution.

* Voting exclusions apply

Resolution 2

Re-election of Dr Kathleen Metters as a Non-Executive Director



Ordinary resolution:

“That Dr Kathleen Metters , who retires and offers herself for re-election as a director of the Company, be re-elected as a non-executive director of the Company.”

Resolution 2

Re-election Dr Kathleen Metters as a Non-Executive Director



The Company has received:

654,165,423 proxy votes in favour of the resolution;

1,834,507 proxy votes against the resolution;

177,786 proxy votes abstaining from the resolution;

0 proxy votes excluded from voting;

24,608,743 proxies able to be voted by the chair/board which the chair/board intend to vote in favour of the resolution.

Resolution 3

Approval of the grant of Performance Rights to Mr Gary Phillips, Managing Director and Chief Executive Officer

Ordinary resolution:

“That, for the purposes of the ASX Listing Rule 10.14 and for all other purposes, approval is given for the grant of 2,771,000 zero grant price and zero exercise price employee options (**Performance Rights**) to Mr Gary Phillips or his nominee(s) under the Company’s Performance Rights Plan, as described in the Explanatory Statement accompanying the Notice of Meeting.”

Resolution 3



Approval of the grant of Performance Rights to Mr Gary Phillips, Managing Director and Chief Executive Officer

The Company has received:

635,098,107 proxy votes in favour of the resolution;

6,955,981 proxy votes against the resolution;

11,824,318 proxy votes abstaining from the resolution;

318,102 proxy votes excluded from voting;

26,589,951 proxies able to be voted by the chair/board which the chair/board intend to vote in favour of the resolution.

* Voting exclusions apply

Resolution 4



Approval of the Company's Employee Option Plan/ Performance Rights Plan

Ordinary resolution:

“That, for the purpose of Exception 13(b) of ASX Listing Rule 7.2 and for all other purposes, approval is given for the Company's Employee Option Plan/Performance Rights Plan and for the issue of an aggregate maximum of 163,740,518 options/ Performance Rights under that Employee Option Plan/Performance Rights Plan, as more fully described in the Explanatory Statement accompanying this Notice of Meeting.”

Resolution 4



Approval of the Company's Employee Option Plan/ Performance Rights Plan

The Company has received:

376,369,359 proxy votes in favour of the resolution;

265,692,904 proxy votes against the resolution;

11,816,143 proxy votes abstaining from the resolution;

318,102 proxy votes excluded from voting;

26,589,951 proxies able to be voted by the chair/board which the chair/board intend to vote in favour of the resolution.

* Voting exclusions apply

Resolution 5

Appointment of Auditor



Ordinary resolution:

“That, subject to the consent of the Australian Securities and Investments Commission to the resignation of PricewaterhouseCoopers as current auditor of the Company, William Buck Audit (Vic) Pty Ltd, having consented in writing and been duly nominated in accordance with section 328B(1) of the Corporations Act 2001 (Cth) and for all other purposes, be appointed as auditor of the Company and for the Board of the Company to be authorised to approve their remuneration, with effect from the conclusion of the Meeting, as described in the Explanatory Statement accompanying the Notice of Meeting.”

Resolution 5

Appointment of Auditor



The Company has received:

654,608,680 proxy votes in favour of the resolution;

381,533 proxy votes against the resolution;

1,042,922 proxy votes abstaining from the resolution;

0 proxy votes excluded from voting;

24,753,324 proxies able to be voted by the chair/board which the chair/board intend to vote in favour of the resolution.

* Voting exclusions apply



Close of Voting

Annual General Meeting, 28 November 2024



Thank you for your participation

Annual General Meeting, 28 November 2024